GeoVax to Launch Phase 3 Mpox-Smallpox Vaccine Trial as Governments Prioritize Supply Resilience
GOVX•GeoVax will begin a pivotal Phase 3 trial of its GEO-MVA mpox-smallpox vaccine in H2 2026 under an expedited pathway to expand orthopoxvirus supply and biodefense preparedness. CEO David Dodd says governments and industry now view next-generation vaccine platforms, manufacturing resilience and rapid-response technologies as strategic assets against disease threats.
1. CEO Emphasizes Strategic Vaccine Investments
David Dodd states that vaccine programs for emerging infectious diseases are transitioning from public health initiatives into strategic assets, with governments emphasizing pre-emptive investments in next-generation platforms and rapid-response technologies.
2. GEO-MVA Phase 3 Trial Timeline
GeoVax's priority program, GEO-MVA, is a Modified Vaccinia Ankara–based vaccine targeting mpox and smallpox, set to enter a pivotal Phase 3 clinical trial in the second half of 2026 under an expedited regulatory pathway to expand global orthopoxvirus vaccine supply.
3. Supply-Chain Resilience and Health Security
Stakeholders across the Americas and Europe are prioritizing domestic manufacturing and supply-chain resilience to bolster medical countermeasure capabilities, reflecting broader health-security strategies against accelerating disease emergence driven by travel, urbanization and climate change.
4. Oncology Pipeline and IP Portfolio
Beyond infectious diseases, GeoVax is advancing its oncology candidate Gedeptin through combination strategies following completion of a Phase 1/2 trial, while maintaining a global intellectual property portfolio and exploring strategic partnerships to support both its vaccine and immunotherapy development.
